Clinical Pharmacology and Therapeutics
A Textbook of Clinical Pharmacology and ... - clinicalevidence
A Textbook of Clinical Pharmacology and ... - clinicalevidence
- No tags were found...
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
ADVERSE DRUG REACTION MONITORING/SURVEILLANCE (PHARMACOVIGILANCE) 65<br />
analgesic. Following its release, there were spontaneous reports<br />
to the CSM of photosensitivity <strong>and</strong> onycholysis. Further reports<br />
appeared in the elderly, in whom its half-life is prolonged, of<br />
cholestatic jaundice <strong>and</strong> hepatorenal failure, which was fatal<br />
in eight cases. Benoxaprofen was subsequently taken off the<br />
market when 3500 adverse drug reaction reports were received<br />
with 61 fatalities. The yellow card/black triangle scheme was<br />
also instrumental in the early identification of urticaria <strong>and</strong><br />
cough as adverse effects of angiotensin-converting enzyme<br />
inhibitors. Although potentially the population under study<br />
by this system consists of all the patients using a drug, in fact<br />
under-reporting yields a population that is not uniformly<br />
sampled. Such data can be unrepresentative <strong>and</strong> difficult to<br />
work with statistically, contributing to the paucity of accurate<br />
incidence data for adverse drug reactions.<br />
Systems such as the yellow card scheme (e.g. FDA MedWatch<br />
in the USA) are relatively inexpensive <strong>and</strong> easy to manage,<br />
<strong>and</strong> facilitate ongoing monitoring of all drugs, all consumers<br />
<strong>and</strong> all types of adverse reaction. Reports from the drug regulatory<br />
bodies of 22 countries are collated by the World Health<br />
Organization (WHO) Unit of Drug Evaluation <strong>and</strong> Monitoring<br />
in Geneva. Rapid access to reports from other countries should<br />
be of great value in detecting rare adverse reactions, although<br />
the same reservations apply to this register as apply to<br />
national systems. In addition, this database could reveal geographical<br />
differences in the pattern of untoward drug effects.<br />
CASE–CONTROL STUDIES<br />
A very large number of patients have to be monitored to detect<br />
a rare type B adverse effect. An alternative approach is to identify<br />
patients with a disorder which it is postulated could be<br />
caused by an adverse reaction to a drug, <strong>and</strong> to compare the frequency<br />
of exposure to possible aetiological agents with a control<br />
group. A prior suspicion (hypothesis) must exist to prompt<br />
the setting up of such a study – examples are the possible connection<br />
between irradiation or environmental pollution <strong>and</strong><br />
certain malignancies, especially where they are observed in<br />
clusters. Artefacts can occur as a result of unrecognized bias<br />
from faulty selection of patients <strong>and</strong> controls, <strong>and</strong> the approach<br />
remains controversial among epidemiologists, public health<br />
physicians <strong>and</strong> statisticians. Despite this, there is really no practicable<br />
alternative for investigating a biologically plausible<br />
hypothesis relating to a disease which is so uncommon that it<br />
is unlikely to be represented even in large trial or cohort populations.<br />
This methodology has had notable successes: the association<br />
of stilboestrol with vaginal adenocarcinoma, gatifloxacin<br />
with hypo- <strong>and</strong> hyperglycaemia, <strong>and</strong> salmeterol or fenoterol<br />
use with increased fatality in asthmatics.<br />
INTENSIVE MONITORING<br />
Several hospital-based intensive monitoring programmes are<br />
currently in progress. The Aberdeen–Dundee system abstracts<br />
data from some 70 000 hospital admissions each year, storing<br />
these on a computer file before analysis. The Boston<br />
Collaborative Drug Surveillance Program (BCDSP), involving<br />
selected hospitals in several countries, is even more comprehensive.<br />
In the BCDSP, all patients admitted to specially designated<br />
general wards are included in the analysis. Specially<br />
trained personnel obtain the following information from hospital<br />
patients <strong>and</strong> records:<br />
1. background information (i.e. age, weight, height, etc.);<br />
2. medical history;<br />
3. drug exposure;<br />
4. side effects;<br />
5. outcome of treatment <strong>and</strong> changes in laboratory tests<br />
during hospital admission.<br />
A unique feature of comprehensive drug-monitoring systems<br />
lies in their potential to follow up <strong>and</strong> investigate adverse<br />
reactions suggested by less sophisticated detection systems, or<br />
by isolated case reports in medical journals. Furthermore, the<br />
frequency of side effects can be determined more cheaply than<br />
by a specially mounted trial to investigate a simple adverse<br />
effect. Thus, for example, the risk of developing a rash with<br />
ampicillin was found to be around 7% both by clinical trial<br />
<strong>and</strong> by the BCDSP, which can quantify such associations<br />
almost automatically from data on its files. New adverse reactions<br />
or drug interactions are sought by multiple correlation<br />
analysis. Thus, when an unexpected relationship arises, such<br />
as the 20% incidence of gastro-intestinal bleeding in severely<br />
ill patients treated with ethacrynic acid compared to 4.3%<br />
among similar patients treated with other diuretics, this cannot<br />
be attributed to bias arising from awareness of the hypothesis<br />
during data collection, since the data were collected<br />
before the hypothesis was proposed. Conversely, there is a<br />
possibility of chance associations arising from multiple comparisons<br />
(‘type I’ statistical error), <strong>and</strong> such associations must<br />
be reviewed critically before accepting a causal relationship. It<br />
is possible to identify predisposing risk factors. In the association<br />
between ethacrynic acid <strong>and</strong> gastro-intestinal bleeding,<br />
these were female sex, a high blood urea concentration, previous<br />
heparin administration <strong>and</strong> intravenous administration of<br />
the drug. An important aspect of this type of approach is that<br />
lack of clinically important associations can also be investigated.<br />
Thus, no significant association between aspirin <strong>and</strong><br />
renal disease was found, whereas long-term aspirin consumption<br />
is associated with a decreased incidence of myocardial<br />
infarction, an association which has been shown to be of therapeutic<br />
importance in r<strong>and</strong>omized clinical trials (Chapter 29).<br />
There are plans to extend intensive drug monitoring to cover<br />
other areas of medical practice.<br />
However, in terms of new but uncommon adverse reactions,<br />
the numbers of patients undergoing intensive monitoring<br />
while taking a particular drug will inevitably be too small<br />
for the effect to be detectable. Such monitoring can therefore<br />
only provide information about relatively common, early reactions<br />
to drugs used under hospital conditions. Patients are not<br />
in hospital long enough for detection of delayed effects, which<br />
are among the reactions least likely to be recognized as such<br />
even by an astute clinician.